Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453460 · ClinicalTrials.gov registry record · Phase 2
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
A Phase 2 study of CMV and Allogeneic Stem Cell Transplantation, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06453460 is a Phase 2 study of CMV and Allogeneic Stem Cell Transplantation that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 50 participants, below the 355-participant average among 7 other CMV trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06453460, a Phase 2 study of CMV and Allogeneic Stem Cell Transplantation, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.
Conditions Studied
Interventions
- DRUG Letermovir
- DEVICE CMV T Cell Immunity Panel (CMV-TCIP)
- DIAGNOSTIC_TEST CMV DNA PCR
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453460
The ClinicalTrials.gov registry entry for NCT06453460 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 355-participant average among 7 other CMV trials with a reported enrollment target (86% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with CMV appearing as the primary indexed condition, and to 3 interventions - of which Letermovir is the first listed.
NCT06453460 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06453460 about?
NCT06453460 is a clinical study titled "CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT". This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serolo...
What is the current status of trial NCT06453460?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-06-27. Estimated completion is 2029-06.
What conditions does trial NCT06453460 study?
This clinical trial studies the following conditions: CMV, Allogeneic Stem Cell Transplantation.
What interventions are being tested in trial NCT06453460?
The interventions under investigation include: Letermovir (DRUG), CMV T Cell Immunity Panel (CMV-TCIP) (DEVICE), CMV DNA PCR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06453460?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06453460 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CMV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
ACTIVE NOT RECRUITING · Phase 2
-
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RECRUITING
-
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
RECRUITING · Phase 1
-
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 3
-
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
ACTIVE NOT RECRUITING
-
Cytotoxic T Cells to Prevent Virus Infections
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.